Literature DB >> 5156708

Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis.

A G Mowat, J Baum.   

Abstract

Using a new in vitro method of measuring the chemotaxis of polymorphonuclear leukocytes from peripheral blood, a chemotactic index has been calculated. The mean chemotactic index of 320 in 24 patients with definite rheumatoid arthritis, was significantly less (P < 0.0005) than the mean of 555 in 24 normal controls matched for age and sex. The mean chemotactic index of 435 in eight patients with juvenile rheumatoid arthritis was also significantly less (P < 0.01) than that of 553 in similarly matched controls. The chemotactic index could not be correlated with age, sex, disease activity, drugs used in treatment, latex titer, immunoglobulin levels, or protein coating on the cells. However, there was a correlation between the chemotactic index and the serum complement B(1e)/B(1a) value (P < 0.01) in 17 patients with adult onset rheumatoid arthritis. Although the serum complement B(1e)/B(1a) values were within the normal range, the lowest chemotactic indices were associated with the lowest complement values. The chemotactic indices in three patients with severe connective tissue disease (seropositive rheumatoid arthritis, systemic lupus erythematosus, and polymyositis) returned to normal after 5 days' treatment with 60 mg of prednisolone per day. Incubation of the cells from patients with rheumatoid arthritis with hydrocortisone in vitro failed to alter the chemotactic indices. Prior incubation of normal cells with purified rheumatoid factor complexes, rheumatoid serum, or macromolecules of iron dextran impaired their chemotaxis. It is suggested that phagocytosis of complexes in vivo is a possible mechanism by which the chemotaxis of the polymorphonuclear leukocytes of patients with rheumatoid arthritis is impaired. This impairment in chemotaxis may explain the increased incidence of bacterial infection, both during life and as a cause of death in these patients.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5156708      PMCID: PMC292203          DOI: 10.1172/JCI106754

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes.

Authors:  A J SBARRA; M L KARNOVSKY
Journal:  J Biol Chem       Date:  1959-06       Impact factor: 5.157

2.  Chemotaxis of polymorphonuclear leukocytes.

Authors:  P A Ward
Journal:  Biochem Pharmacol       Date:  1968-03       Impact factor: 5.858

3.  Complement system in synovial fluids from patients with rheumatoid arthritis.

Authors:  H Sonozaki; M Torisu
Journal:  Ann Rheum Dis       Date:  1970-03       Impact factor: 19.103

Review 4.  Hypersensitivity and infection in the pathogenesis of the rheumatic diseases.

Authors:  K W Walton
Journal:  Int Rev Exp Pathol       Date:  1968

5.  Elevated IgG antiglobulins in patients with seronegative rheumatoid arthritis.

Authors:  G Torrigiani; I M Roitt; K N Lloyd; M Corbett
Journal:  Lancet       Date:  1970-01-03       Impact factor: 79.321

6.  Survivorship and death in rheumatoid arthritis.

Authors:  J Uddin; A S Kraus; H G Kelly
Journal:  Arthritis Rheum       Date:  1970 Mar-Apr

7.  Brucella immunization in patients with seropositive and seronegative rheumatoid arthritis.

Authors:  M Waller; H M Ellman; E C Toone
Journal:  Acta Rheumatol Scand       Date:  1966

8.  Pulmonary lesions and rheumatoid arthritis.

Authors:  W C Walker; V Wright
Journal:  Medicine (Baltimore)       Date:  1968-11       Impact factor: 1.889

9.  A simplified method for the measurement of chemotaxis of polymorphonuclear leukocytes from human blood.

Authors:  J Baum; A G Mowat; J A Kirk
Journal:  J Lab Clin Med       Date:  1971-03

10.  The chemosuppression of chemotaxis.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1966-08-01       Impact factor: 14.307

View more
  59 in total

1.  Suppressive effect of IgA soluble immune complexes on neutrophil chemotaxis.

Authors:  S Ito; H Mikawa; K Shinomiya; T Yoshida
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

2.  [Granulocyte dysfunction. Part II. Secondary defects. (authors transl)].

Authors:  D Niethammer; A Wildfeuer; E Kleihauer; O Haferkamp
Journal:  Klin Wochenschr       Date:  1975-08-15

3.  Leucocyte function in ulcerative colitis. Quantitative leucocyte mobilisation to skin windows and in vitro function of blood leucocytes.

Authors:  J H Wandall; V Binder
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

4.  Leucocyte function in patients with rheumatoid arthritis: quantitative in-vivo leucocyte mobilisation and in-vitro functions of blood and exudate leucocytes.

Authors:  J H Wandall
Journal:  Ann Rheum Dis       Date:  1985-10       Impact factor: 19.103

5.  Inhibition of neutrophil migration by sera from patients with rheumatoid arthritis.

Authors:  A S Kemp; P Roberts-Thomson; S H Neoh; S Brown
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

6.  GM-CSF and G-CSF in Felty's syndrome.

Authors:  D R Wagner; C Combe; U Gresser
Journal:  Clin Investig       Date:  1993-02

7.  Effects of tenoxicam on neutrophil chemotaxis in rheumatoid arthritis and healthy controls.

Authors:  Z Hascelik; G Hascelik; R Celiker; M Ozalp
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

8.  Polymorphonuclear cell function in rheumatoid arthritis and in Felty's syndrome.

Authors:  G B Howe; J N Fordham; K A Brown; H L Currey
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

9.  An inhibitor of leucocyte movement in the plasma of patients with rheumatoid arthritis.

Authors:  J R Walker; M J Smith
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

10.  Interaction of circulating immune complexes with granulocyte function in patients with rheumatoid arthritis.

Authors:  B Bültmann; R Geitner; H Seibold; G Kratsch; O Haferkamp
Journal:  Klin Wochenschr       Date:  1980-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.